This systematic review attempted to summarize the associations between the Asn291Ser variant in the lipoprotein lipase (LPL) gene and dyslipidemia, the risk of type 2 diabetes mellitus (T2DM), and coronary heart disease (CHD). In addition, the relationships between the Asn291-Ser variant and other metabolic diseases such as obesity and high blood pressure were also investigated in this systematic review. We systematically reviewed the literature by means of a meta-analysis. Twenty-one articles, including 19,246 white subjects, were selected for this meta-analysis. The summary standardized mean difference (SMD) of plasma triglyceride (TG) for carriers compared with noncarriers of the Asn291Ser variant was 3.23 (P , 0.00001). The summary SMD of plasma HDL-cholsterol (HDL-C) for carriers compared with noncarriers of the Asn291Ser variant was À3.42 (P , 0.0001). The summary SMD of the association of the Asn291Ser variant with plasma TG increased with increasing age and weight gain. Significant interactions between the LPL Asn291Ser variant and fasting glucose, T2DM, and CHD were seen (P 5 0.02, 0.04, and 0.01, respectively). No significant interactions were seen between the LPL Asn291-Ser variant and body mass index, waist-hip ratio, and blood pressure (P . 0.05). This meta-analysis indicates that the Asn291Ser variant in the LPL gene is a risk factor for dyslipidemia, characterized by hypertriglyceridemia and low HDL-C levels. And the Asn291Ser variant in the LPL gene predisposes to more severe dyslipidemia with increasing age and weight gain. Also, this meta-analysis shows that the LPL Asn291Ser variant is associated with CHD and T2DM.-Hu, Y., W. Liu, R. Huang, and X. Zhang. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases. J. Lipid Res. 2006Res. . 47: 1908Res. -1914 Supplementary key words dyslipidemia . type 2 diabetes mellitus . coronary heart disease . obesity . high blood pressure Lipoprotein lipase (LPL, E.C.3.1.1.34) is a key enzyme that hydrolyzes triglyceride (TG) contained in the core of both chylomicrons and VLDL particles (1-4). Because of this central role, the function of LPL could be associated with dyslipidemia and characterized by hypertriglyceridemia and low HDL-cholesterol (HDL-C) levels. The Asn291Ser variant in the LPL gene was first identified in 1994 (5). Since then, many studies have examined the association between the Asn291Ser variant in the LPL gene and dyslipidemia (6-26). It has been observed that the Asn291Ser variant in the LPL gene occurs more frequently in dyslipidemia subjects than in control subjects. Based on 13 studies published up to 1997 (27), Asn291Ser heterozygous carriers had an average increase in plasma TG of 31% and an average decrease in HDL-C of 0.12 mM (P , 0.001). However, since then, a number of other studies have been published in which no association was observed (10,18,20,21,24). In addition to study power and other methodological issues, interactions with important dyslipidemic risk...